Cytokinetics’ Aficamten Data Could Be Best In Class, Cardiologists Say
CEO Robert Blum Talked To Scrip
The company released detailed data from the Phase III SEQUOIA-HCM trial testing the cardiac myosin inhibitor in patients with obstructive hypertrophic cardiomyopathy at Heart Failure 2024.
